Chronic Kidney Disease

Jackson Williams is vice president, public policy at Dialysis Patient Citizens. Previously he worked at the Centers for Medicare and Medicaid Services (CMS); was a health services researcher in the AARP Public Policy Institute; and a lobbyist on health policy issues for 3 nonprofit associations. His more than 2 decades of experience monitoring, studying, and overseeing federal demonstration projects include time as a project officer at CMMI and serving as the consumer representative on a Medicare pilot site’s governing body.

If results from FIGARO-DKD are as positive as those of FIDELIO-DKD, the field will work aggressively to get the message out, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.

In the FIDELIO-DKD trial researchers purposely recruited centers that had very large African American databases, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine.

A new analysis of CREDENCE data showed that the sodium-glucose cotransporter 2 (SGLT2) inhibitor worked in advanced disease and without causing acute kidney injury.

The FIDELIO-DKD program is perhaps just the beginning of seeing how finerenone can be used, said Rajiv Agarwal, MD, MS, FASN, a professor of medicine at Indiana University School of Medicine and a staff physician at the Veterans Affairs Medical Center in Indianapolis, Indiana.

Primary care physicians did not refer the majority of patients with severe nephropathy to specialists; nonreferred patients had fewer comorbidities and might be better kidney transplant candidates.

Authors from the American Society of Nephrology and Kidney Care Partners discuss the response of the kidney care community to the COVID-19 pandemic.

The federal illegality and Schedule I listing of cannabis significantly impair our ability to conduct any kind of prospective clinical research, said Joshua L Rein, DO, FASN, a nephrologist at Mt. Sinai Hospital in New York City.

A pair of abstracts presented at Kidney Week 2020 underscore the relationship between social determinants of health (SDOH) and chronic kidney disease (CKD) in military populations and the challenges of tracking these factors.

New results from EMPEROR-Reduced presented at Kidney Week 2020.

Prompted by students, the medical school overturned a longstanding diagnostic protocol that was not well-founded in evidence.

For-profit dialysis centers are spending heavily to defeat the measure.

The recent focus on disparities in health care comes through in the call to action.

The FDA action follows presentation of results in August during the European Society of Cardiology 2020 Virtual Congress.

A new analysis shows that ertugliflozin matched renal results seen in trials for a pair of rival sodium glucose cotransporter 2 (SGLT2) inhibitors.

Nivolumab, a checkpoint inhibitor, and cabozantinib, a targeted therapy, produced dramatic results when used in combination for patients with newly diagnosed advanced kidney cancer.

Researchers suggest that clinical trial design could be shaped by measuring reductions in urinary protein.

Trump administration officials said the new payment incentives represent the biggest change in kidney care in decades.

Kidney cancer rose at least 3% a year during the years studied among adolescents and young adults, according to data from the American Cancer Society.

Members of Congress introduce a bill to force Medicare to cover a drug they say will protect CKD patients during the COVID-19 pandemic.

A study suggests cardiac rehabilitation offers the most benefits to patients who start out with more advanced renal disease.

In the past 30 years, we've never seen a heart failure drug that has had such a beneficial effect on the kidneys, said Milton Packer, MD, a distinguished scholar in cardiovascular science at Baylor University Medical Center in Dallas, and chair of the department of clinical sciences at the University of Texas Southwestern Medical School.

Kidney failure is one of the expensive conditions in health care, but new results from the DAPA-CKD trial could change the equation in favor of prevention.

A Dutch study shows how genetic testing can help couples avoid passing devastating kidney diseases to their children, but it raises issues of disparities.

A proprietary algorithm can help payers identify patients at high risk of progressive chronic kidney disease.